Healthcare & Pharmaceuticals
LOS ANGELES, Aug. 25 - The attorney general of California sued 39 drug companies on Thursday, accusing them of bilking the state of hundreds of millions of dollars by overcharging for medicines.
Bayer doesn't just make aspirin--it's a major producer of chemicals and drugs with a dubious corporate record. So how did it get into a partnership with the UN? A German activist tells how and why.
Gilead Sciences Inc., a California based pharmaceutical company, has avoided paying $10 billion in taxes by moving its patents to Ireland. This is despite the fact that one of its most profitable drugs was developed with U.S. taxpayer money, according to a new report from Americans for Tax Fairness.
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.
In a move activists hoped would lead to a flood of affordable AIDS medication to Africa, the pharmaceutical industry dropped its suit Thursday challenging a South African law many say would allow the government to import or produce generic versions of the drugs.
JOHANNESBURG -- A severe shortage of two antiretrovirals (ARVs) produced by leading pharmaceutical Bristol-Myers Squibb in Kenya, could have critical repercussions for patients, says Medecines sans Frontieres (MSF).
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.
When individuals sue major corporations, the odds are stacked against them. One woman's fight against an insurance giant details those odds and what it takes to beat them.
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.
The decision by PH Kurian, the controller general of patents, designs and trademarks in India, to allow a local company to manufacture Sorafenib, a drug used to treat advanced kidney cancer and liver cancer, is a welcome move that supports the access of poor people to cheap life-saving drugs.